Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
Identifieur interne : 000677 ( Main/Exploration ); précédent : 000676; suivant : 000678Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
Auteurs : J. P. H. Wilding [Royaume-Uni] ; G. Charpentier [France] ; P. Hollander [États-Unis] ; G. González-Gálvez [Mexique] ; C. Mathieu [Belgique] ; F. Vercruysse [Belgique] ; K. Usiskin [États-Unis] ; G. Law [États-Unis] ; S. Black [États-Unis] ; W. Canovatchel [États-Unis] ; G. Meininger [États-Unis]Source :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2013-12.
Abstract
Canagliflozin is a sodium glucose co‐transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double‐blind, placebo‐controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add‐on to metformin plus sulphonylurea in patients with T2DM.
Url:
DOI: 10.1111/ijcp.12322
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001606
- to stream Istex, to step Curation: 001559
- to stream Istex, to step Checkpoint: 000334
- to stream Main, to step Merge: 000678
- to stream Main, to step Curation: 000677
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial</title><author><name sortKey="Wilding, J P H" sort="Wilding, J P H" uniqKey="Wilding J" first="J. P. H." last="Wilding">J. P. H. Wilding</name></author><author><name sortKey="Charpentier, G" sort="Charpentier, G" uniqKey="Charpentier G" first="G." last="Charpentier">G. Charpentier</name></author><author><name sortKey="Hollander, P" sort="Hollander, P" uniqKey="Hollander P" first="P." last="Hollander">P. Hollander</name></author><author><name sortKey="Gonzalez Lvez, G" sort="Gonzalez Lvez, G" uniqKey="Gonzalez Lvez G" first="G." last="González-Gálvez">G. González-Gálvez</name></author><author><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name></author><author><name sortKey="Vercruysse, F" sort="Vercruysse, F" uniqKey="Vercruysse F" first="F." last="Vercruysse">F. Vercruysse</name></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name></author><author><name sortKey="Law, G" sort="Law, G" uniqKey="Law G" first="G." last="Law">G. Law</name></author><author><name sortKey="Black, S" sort="Black, S" uniqKey="Black S" first="S." last="Black">S. Black</name></author><author><name sortKey="Canovatchel, W" sort="Canovatchel, W" uniqKey="Canovatchel W" first="W." last="Canovatchel">W. Canovatchel</name></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4523A0F87E08EB9E953C67E37A8849A67D0E5F2C</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/ijcp.12322</idno><idno type="url">https://api.istex.fr/document/4523A0F87E08EB9E953C67E37A8849A67D0E5F2C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001606</idno><idno type="wicri:Area/Istex/Curation">001559</idno><idno type="wicri:Area/Istex/Checkpoint">000334</idno><idno type="wicri:doubleKey">1368-5031:2013:Wilding J:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">000678</idno><idno type="wicri:Area/Main/Curation">000677</idno><idno type="wicri:Area/Main/Exploration">000677</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial</title><author><name sortKey="Wilding, J P H" sort="Wilding, J P H" uniqKey="Wilding J" first="J. P. H." last="Wilding">J. P. H. Wilding</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Obesity and Endocrinology, University of Liverpool, Liverpool</wicri:regionArea><wicri:noRegion>Liverpool</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Charpentier, G" sort="Charpentier, G" uniqKey="Charpentier G" first="G." last="Charpentier">G. Charpentier</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Diabetes Sud‐Francilien Hospital, Centre d'Études et de Recherche pour l'Intensification du Traitement du Diabète (CERITD), Corbeil‐Essonnes</wicri:regionArea><wicri:noRegion>Corbeil‐Essonnes</wicri:noRegion><wicri:noRegion>Corbeil‐Essonnes</wicri:noRegion></affiliation></author><author><name sortKey="Hollander, P" sort="Hollander, P" uniqKey="Hollander P" first="P." last="Hollander">P. Hollander</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Baylor University Medical Center, TX, Dallas</wicri:regionArea><wicri:noRegion>Dallas</wicri:noRegion></affiliation></author><author><name sortKey="Gonzalez Lvez, G" sort="Gonzalez Lvez, G" uniqKey="Gonzalez Lvez G" first="G." last="González-Gálvez">G. González-Gálvez</name><affiliation wicri:level="1"><country xml:lang="fr">Mexique</country><wicri:regionArea>Instituto Jalisciense de Investigacion en Diabetes y Obesidad, Guadalajara</wicri:regionArea><wicri:noRegion>Guadalajara</wicri:noRegion></affiliation></author><author><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Clinical and Experimental Endocrinology, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vercruysse, F" sort="Vercruysse, F" uniqKey="Vercruysse F" first="F." last="Vercruysse">F. Vercruysse</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Law, G" sort="Law, G" uniqKey="Law G" first="G." last="Law">G. Law</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Black, S" sort="Black, S" uniqKey="Black S" first="S." last="Black">S. Black</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Canovatchel, W" sort="Canovatchel, W" uniqKey="Canovatchel W" first="W." last="Canovatchel">W. Canovatchel</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author><author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Janssen Research & Development LLC, NJ, Raritan</wicri:regionArea><wicri:noRegion>Raritan</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Clinical Practice</title><title level="j" type="abbrev">Int J Clin Pract</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-12">2013-12</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1267">1267</biblScope><biblScope unit="page" to="1282">1282</biblScope></imprint><idno type="ISSN">1368-5031</idno></series><idno type="istex">4523A0F87E08EB9E953C67E37A8849A67D0E5F2C</idno><idno type="DOI">10.1111/ijcp.12322</idno><idno type="ArticleID">IJCP12322</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Canagliflozin is a sodium glucose co‐transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double‐blind, placebo‐controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add‐on to metformin plus sulphonylurea in patients with T2DM.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>France</li><li>Mexique</li><li>Royaume-Uni</li><li>États-Unis</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Wilding, J P H" sort="Wilding, J P H" uniqKey="Wilding J" first="J. P. H." last="Wilding">J. P. H. Wilding</name></noRegion><name sortKey="Wilding, J P H" sort="Wilding, J P H" uniqKey="Wilding J" first="J. P. H." last="Wilding">J. P. H. Wilding</name></country><country name="France"><noRegion><name sortKey="Charpentier, G" sort="Charpentier, G" uniqKey="Charpentier G" first="G." last="Charpentier">G. Charpentier</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Hollander, P" sort="Hollander, P" uniqKey="Hollander P" first="P." last="Hollander">P. Hollander</name></noRegion><name sortKey="Black, S" sort="Black, S" uniqKey="Black S" first="S." last="Black">S. Black</name><name sortKey="Canovatchel, W" sort="Canovatchel, W" uniqKey="Canovatchel W" first="W." last="Canovatchel">W. Canovatchel</name><name sortKey="Law, G" sort="Law, G" uniqKey="Law G" first="G." last="Law">G. Law</name><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name></country><country name="Mexique"><noRegion><name sortKey="Gonzalez Lvez, G" sort="Gonzalez Lvez, G" uniqKey="Gonzalez Lvez G" first="G." last="González-Gálvez">G. González-Gálvez</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name></noRegion><name sortKey="Vercruysse, F" sort="Vercruysse, F" uniqKey="Vercruysse F" first="F." last="Vercruysse">F. Vercruysse</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000677 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000677 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4523A0F87E08EB9E953C67E37A8849A67D0E5F2C
|texte= Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
}}
| This area was generated with Dilib version V0.6.25. |  |